GLAND2023-04-012023-06-30 GLAND2023-04-012023-06-30in-bse-fin:OneOperatingExpenses01Member GLAND2023-04-012023-06-30in-bse-fin:OneOperatingExpenses02Member GLAND2023-06-30 GLAND2023-04-012023-06-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member GLAND2023-04-012023-06-30in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 543245 GLAND NOTLISTED Gland Pharma Limited Equity 2023-04-01 2024-03-31 2023-08-07 2023-07-27 INR Millions First quarter 15:00:00 16:00:00 2023-08-07 2023-08-07 Not applicable Single segment Pharmaceuticals 2023-04-01 2023-06-30 Unaudited Consolidated 12086930000.00 375420000.00 12462350000.00 4655310000.00 37920000.00 -164200000.00 2550040000.00 49150000.00 653150000.00 2068320000.00 9849690000.00 2612660000.00 0.00 2612660000.00 590900000.00 80740000.00 671640000.00 0.00 1941020000.00 0.00 0.00 0.00 0.00 1941020000.00 -246450000.00 1694570000.00 1941020000.00 0.00 1694570000.00 0.00 164700000.00 1 11.79 11.78 0.00 0.00 11.79 11.78 1. In terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) 2015, this Statement of Unaudited Consolidated Financial Results for the quarter ended June 30, 2023 ( Unaudited Consolidated Financial Results ) of Gland Pharma Limited (the Holding Company or the Company ) and its subsidiaries, (the Holding Company and its subsidiaries together referred to as the Group ) has been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on August 07, 2023 and have been subject to a limited review by the statutory auditors of the Company. 2. The Unaudited Consolidated Financial Results of the Group have been prepared in accordance with the Indian Accounting Standards notified under Section 133 of the Companies Act 2013, as amended read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) 2015, as amended (the Listing requirements ). 3. The figures of the quarter ended March 31, 2023 are the balancing figures between audited figures in respect of the full previous financial year and the published unaudited year-to-date figures up to the end of the third quarter of the previous financial year, which were subjected to a limited review. For points 4 to 8, refer the signed results uploaded in the stock exchange Other expenses 1570400000.00 Power and fuel 497920000.00 Re-measurement (loss)/gain on employee defined benefit plans -7520000.00 -7520000.00 -1890000.00 Exchange differences on translation of net investment in foreign operations -240820000.00 -240820000.00 0.00